General Information of Drug Transporter (DT)
DT ID	DTD0126 Transporter Info
Gene Name	SLC19A1
Protein Name	Folate transporter 1
Gene ID	6573
UniProt ID	P41440
Genetic Polymorphisms of DT (GPD)
Genetic Polymorphism	rs1051266
Site of GPD	chr21:45537880 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>C / T>G
Minor Allele Frequency	C=0.4886/2447 (Global)
Allele C	Click to Show/Hide the Full List of Affected Drugs:         44 Drugs in Total
Methotrexate	Drug Info	Precursor Cell Lymphoblastic Leukemia-Lymphoma	Correlated with the increased vomiting in patients (compare with Allele T); Irrelevant to the differences in plasma or cerebrospinal fluid homocysteine levels or in toxicity in patients (compare with Allele T); Irrelevant to the drug response in patients (compare with Allele T)		[ 1], [ 2], [ 3]
Methotrexate	Drug Info	Leukemia	Irrelevant to the nephrotoxicity risk in patients (compare with Allele T); Irrelevant to the prolonged high drug concentrations risk patients (compare with Allele T)		[ 4]
Methotrexate	N.A.	Drug Toxicity	Allele C is not associated with catalytic activity of TYMS when treated with methotrexate in lymphoblasts from pediatric ALL patients.		[ 5]
Methotrexate	N.A.	Drug Toxicity	Allele C is not associated with response to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T.		[ 1]
Methotrexate	N.A.	Nephrotoxicity	Allele C is not associated with risk of nephrotoxicity when treated with methotrexate in children with Leukemia as compared to allele T.		[ 4]
Methotrexate	N.A.	Adverse Events	Allele C is not associated with risk of prolonged high concentrations of methotrexate in children with Leukemia as compared to allele T.		[ 4]
Methotrexate	N.A.	Drug Toxicity	Allele C is not associated with Drug Toxicity when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T.		[ 3]
Tenofovir	N.A.	Drug Toxicity	Allele C is not associated with clearance of tenofovir in people with HIV Infections as compared to allele T.		[ 6]
Methotrexate	N.A.	Drug Toxicity	Allele C is not associated with exposure to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T.		[ 7]
Methotrexate	N.A.	Progression-free Survival	Allele C is not associated with concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T.		[ 8]
Methotrexate	N.A.	Drug Toxicity	Allele C is not associated with Drug Toxicity when treated with methotrexate in people with Arthritis, Rheumatoid.		[ 9]
Methotrexate	N.A.	Drug Toxicity	Allele C is not associated with likelihood of Drug Toxicity or Nausea due to methotrexate in children with Arthritis, Juvenile Rheumatoid as compared to allele T.		[ 10]
Methotrexate	N.A.	Nausea	Allele C is not associated with likelihood of Drug Toxicity or Nausea due to methotrexate in children with Arthritis, Juvenile Rheumatoid as compared to allele T.		[ 10]
Methotrexate	N.A.	Toxic Liver Disease	Allele C is associated with increased vomiting when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T.		[ 2]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Allele C is not associated with response to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T.		[ 1]
Methotrexate	N.A.	Neoplasms	Allele C is not associated with response to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T.		[ 1]
Methotrexate	N.A.	Neoplasms	Allele C is not associated with Drug Toxicity when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T.		[ 3]
Methotrexate	N.A.	Neoplasms	Allele C is associated with increased vomiting when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T.		[ 2]
Methotrexate	N.A.	Neoplasms	Allele C is not associated with risk of nephrotoxicity when treated with methotrexate in children with Leukemia as compared to allele T.		[ 4]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Allele C is not associated with concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T.		[ 8]
Methotrexate	N.A.	Burkitt Lymphoma	Allele C is not associated with concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T.		[ 8]
Methotrexate	N.A.	Leukemia	Allele C is not associated with concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T.		[ 8]
Methotrexate	N.A.	Lymphoma, T-cell	Allele C is not associated with concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T.		[ 8]
Methotrexate	N.A.	Neoplasms	Allele C is not associated with concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T.		[ 8]
Methotrexate	N.A.	Osteosarcoma	Allele C is not associated with concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T.		[ 8]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Allele C is not associated with exposure to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T.		[ 7]
Methotrexate	N.A.	Burkitt Lymphoma	Allele C is not associated with exposure to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T.		[ 7]
Methotrexate	N.A.	Leukemia	Allele C is not associated with exposure to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T.		[ 7]
Methotrexate	N.A.	Lymphoma, T-cell	Allele C is not associated with exposure to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T.		[ 7]
Methotrexate	N.A.	Neoplasms	Allele C is not associated with exposure to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T.		[ 7]
Methotrexate	N.A.	Osteosarcoma	Allele C is not associated with exposure to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T.		[ 7]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Allele C is not associated with risk of prolonged high concentrations of methotrexate in children with Leukemia as compared to allele T.		[ 4]
Methotrexate	N.A.	Burkitt Lymphoma	Allele C is not associated with risk of prolonged high concentrations of methotrexate in children with Leukemia as compared to allele T.		[ 4]
Methotrexate	N.A.	Leukemia	Allele C is not associated with risk of prolonged high concentrations of methotrexate in children with Leukemia as compared to allele T.		[ 4]
Methotrexate	N.A.	Lymphoma, T-cell	Allele C is not associated with risk of prolonged high concentrations of methotrexate in children with Leukemia as compared to allele T.		[ 4]
Methotrexate	N.A.	Osteosarcoma	Allele C is not associated with risk of prolonged high concentrations of methotrexate in children with Leukemia as compared to allele T.		[ 4]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Allele C is not associated with catalytic activity of TYMS when treated with methotrexate in lymphoblasts from pediatric ALL patients.		[ 5]
Methotrexate	N.A.	Burkitt Lymphoma	Allele C is not associated with catalytic activity of TYMS when treated with methotrexate in lymphoblasts from pediatric ALL patients.		[ 5]
Methotrexate	N.A.	Leukemia	Allele C is not associated with catalytic activity of TYMS when treated with methotrexate in lymphoblasts from pediatric ALL patients.		[ 5]
Methotrexate	N.A.	Lymphoma, T-cell	Allele C is not associated with catalytic activity of TYMS when treated with methotrexate in lymphoblasts from pediatric ALL patients.		[ 5]
Methotrexate	N.A.	Neoplasms	Allele C is not associated with catalytic activity of TYMS when treated with methotrexate in lymphoblasts from pediatric ALL patients.		[ 5]
Methotrexate	N.A.	Osteosarcoma	Allele C is not associated with catalytic activity of TYMS when treated with methotrexate in lymphoblasts from pediatric ALL patients.		[ 5]
Methotrexate	N.A.	Rheumatoid Arthritis	Allele C is not associated with likelihood of Drug Toxicity or Nausea due to methotrexate in children with Arthritis, Juvenile Rheumatoid as compared to allele T.		[ 10]
Methotrexate	N.A.	Rheumatoid Arthritis	Allele C is not associated with Drug Toxicity when treated with methotrexate in people with Arthritis, Rheumatoid.		[ 9]
Allele T	Click to Show/Hide the Full List of Affected Drugs:         27 Drugs in Total
Folic Acid	Drug Info	Rheumatoid Arthritis	Correlated with the increased drug response in patients (compare with allele C)		[ 11]
Sulfasalazine	Drug Info	Rheumatoid Arthritis	Correlated with the increased drug response in patients (compare with allele C)		[ 11]
Hydroxychloroquine	Drug Info	Rheumatoid Arthritis	Correlated with the increased drug response in patients (compare with allele C)		[ 11]
Methotrexate	Drug Info	Rheumatoid Arthritis	Correlated with the increased drug response in patients (compare with allele C); Correlated with the increased drug response in patients (compare with allele C); Irrelevant to the drug response in patients (compare with allele C)		[ 11], [ 12], [ 13]
Methotrexate	Drug Info	Precursor Cell Lymphoblastic Leukemia-Lymphoma	Correlated with the worse prognose in patients (compare with genotype CC)		[ 14]
Methotrexate	N.A.	Drug Toxicity	Allele T is associated with worse prognoses when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.		[ 14]
Mercaptopurine	N.A.	Drug Toxicity	Allele T is not associated with Drug Toxicity when treated with mercaptopurine and methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma.		[ 15]
Methotrexate	N.A.	Drug Toxicity	Allele T is not associated with Drug Toxicity when treated with mercaptopurine and methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma.		[ 15]
Methotrexate	N.A.	Drug-induced Liver Injury	Allele T is associated with increased drug-induced liver injury when treated with methotrexate in people with Psoriasis as compared to allele C.		[ 16]
Methotrexate	N.A.	Thrombocytopenia	Allele T is not associated with response to methotrexate in people with Arthritis, Rheumatoid as compared to allele C.		[ 17]
Folic Acid	N.A.	Drug Toxicity	Allele T is associated with increased response to folic acid, hydroxychloroquine, methotrexate and sulfasalazine in people with Arthritis, Rheumatoid as compared to allele C.		[ 11]
Hydroxychloroquine	N.A.	Drug Toxicity	Allele T is associated with increased response to folic acid, hydroxychloroquine, methotrexate and sulfasalazine in people with Arthritis, Rheumatoid as compared to allele C.		[ 11]
Methotrexate	N.A.	Drug Toxicity	Allele T is associated with increased response to folic acid, hydroxychloroquine, methotrexate and sulfasalazine in people with Arthritis, Rheumatoid as compared to allele C.		[ 11]
Sulfasalazine	N.A.	Drug Toxicity	Allele T is associated with increased response to folic acid, hydroxychloroquine, methotrexate and sulfasalazine in people with Arthritis, Rheumatoid as compared to allele C.		[ 11]
Methotrexate	N.A.	Drug Toxicity	Allele T is associated with increased response to methotrexate in people with Arthritis, Rheumatoid as compared to allele C.		[ 12]
Methotrexate	N.A.	Progression-free Survival	Allele T is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele C.		[ 18]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Allele T is associated with worse prognoses when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.		[ 14]
Methotrexate	N.A.	Neoplasms	Allele T is associated with worse prognoses when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.		[ 14]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Allele T is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele C.		[ 18]
Methotrexate	N.A.	Burkitt Lymphoma	Allele T is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele C.		[ 18]
Methotrexate	N.A.	Leukemia	Allele T is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele C.		[ 18]
Methotrexate	N.A.	Lymphoma, T-cell	Allele T is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele C.		[ 18]
Methotrexate	N.A.	Neoplasms	Allele T is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele C.		[ 18]
Methotrexate	N.A.	Osteosarcoma	Allele T is not associated with clearance of methotrexate in people with Osteosarcoma as compared to allele C.		[ 18]
Methotrexate	N.A.	Rheumatoid Arthritis	Allele T is associated with increased response to methotrexate in people with Arthritis, Rheumatoid as compared to allele C.		[ 19]
Methotrexate	N.A.	Rheumatoid Arthritis	Allele T is not associated with response to methotrexate in people with Arthritis, Rheumatoid as compared to allele C.		[ 13]
Methotrexate	N.A.	Rheumatoid Arthritis	Allele T is associated with increased response to folic acid, hydroxychloroquine, methotrexate and sulfasalazine in people with Arthritis, Rheumatoid as compared to allele C.		[ 11]
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:         39 Drugs in Total
Irinotecan	Drug Info	Colorectal Neoplasm	Correlated with the increased drug response in patients (compare with Genotypes CT + TT)		[ 20]
Fluorouracil	Drug Info	Colorectal Neoplasm	Correlated with the increased drug response in patients (compare with Genotypes CT + TT)		[ 20]
Leucovorin	Drug Info	Colorectal Neoplasm	Correlated with the increased drug response in patients (compare with Genotypes CT + TT)		[ 20]
Methotrexate	Drug Info	Rheumatoid Arthritis	Correlated with the increased drug toxicity risk in patients (compare with Genotypes CT + TT)		[ 21]
Mercaptopurine	Drug Info	Precursor Cell Lymphoblastic Leukemia-Lymphoma	Correlated with the increased likelihood of toxic liver disease in patients (compare with genotypes tt + Ct)		[ 22]
Leucovorin	Drug Info	Precursor Cell Lymphoblastic Leukemia-Lymphoma	Correlated with the increased likelihood of toxic liver disease in patients (compare with genotypes tt + Ct)		[ 22]
Methotrexate	Drug Info	Precursor Cell Lymphoblastic Leukemia-Lymphoma	Correlated with the increased likelihood of toxic liver disease in patients (compare with genotypes tt + Ct); Correlated with the increased severity of mucositis risk in patients (compare with Genotypes CT + TT)		[ 22], [ 23]
Methotrexate	Drug Info	Osteosarcoma	Correlated with the increased overall survival in patients (compare with Genotype TT)		[ 24]
Capecitabine	Drug Info	Colorectal Neoplasm	Correlated with the increased drug response in patients (compare with Genotypes CT + TT)		[ 20]
Methotrexate	N.A.	Drug Toxicity	Genotype CC is associated with increased risk of Drug Toxicity when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotypes CT + TT.		[ 21]
Cyclosporine	N.A.	Graft Vs Host Disease	Genotype CC is associated with decreased risk of Graft vs Host Disease when treated with cyclosporine and methotrexate in people with Hematopoietic stem cell transplantation as compared to genotypes CT + TT.		[ 25]
Methotrexate	N.A.	Graft Vs Host Disease	Genotype CC is associated with decreased risk of Graft vs Host Disease when treated with cyclosporine and methotrexate in people with Hematopoietic stem cell transplantation as compared to genotypes CT + TT.		[ 25]
Methotrexate	N.A.	Drug Toxicity	Genotype CC is associated with decreased risk of Drug Toxicity due to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CT + TT.		[ 26]
Methotrexate	N.A.	Overall Survival	Genotype CC is associated with increased overall survival when treated with methotrexate in people with Osteosarcoma as compared to genotype TT.		[ 24]
Methotrexate	N.A.	Toxic Liver Disease	Genotype CC is associated with increased severity of mucositis when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CT + TT.		[ 23]
Capecitabine	N.A.	Toxic Liver Disease	Genotype CC is associated with increased response to capecitabine, fluorouracil, irinotecan or leucovorin in people with Colorectal Neoplasms as compared to genotypes CT + TT.		[ 20]
Fluorouracil	N.A.	Toxic Liver Disease	Genotype CC is associated with increased response to capecitabine, fluorouracil, irinotecan or leucovorin in people with Colorectal Neoplasms as compared to genotypes CT + TT.		[ 20]
Irinotecan	N.A.	Toxic Liver Disease	Genotype CC is associated with increased response to capecitabine, fluorouracil, irinotecan or leucovorin in people with Colorectal Neoplasms as compared to genotypes CT + TT.		[ 20]
Leucovorin	N.A.	Toxic Liver Disease	Genotype CC is associated with increased response to capecitabine, fluorouracil, irinotecan or leucovorin in people with Colorectal Neoplasms as compared to genotypes CT + TT.		[ 20]
Leucovorin	N.A.	Toxic Liver Disease	Genotype CC is associated with increased likelihood of Toxic liver disease when treated with leucovorin, mercaptopurine and methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CT + TT.		[ 22]
Mercaptopurine	N.A.	Toxic Liver Disease	Genotype CC is associated with increased likelihood of Toxic liver disease when treated with leucovorin, mercaptopurine and methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CT + TT.		[ 22]
Methotrexate	N.A.	Toxic Liver Disease	Genotype CC is associated with increased likelihood of Toxic liver disease when treated with leucovorin, mercaptopurine and methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CT + TT.		[ 22]
Irinotecan	N.A.	Colorectal Neoplasms	Genotype CC is associated with increased response to capecitabine, fluorouracil, irinotecan or leucovorin in people with Colorectal Neoplasms as compared to genotypes CT + TT.		[ 20]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Genotype CC is associated with increased overall survival when treated with methotrexate in people with Osteosarcoma as compared to genotype TT.		[ 24]
Methotrexate	N.A.	Neoplasms	Genotype CC is associated with increased overall survival when treated with methotrexate in people with Osteosarcoma as compared to genotype TT.		[ 24]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	The current evidence base suggests that there is no significant association between the rs1051266 CC genotype and response to methotrexate in patients with neoplasms. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to methotrexate.		[ 26]
Methotrexate	N.A.	Neoplasms	The current evidence base suggests that there is no significant association between the rs1051266 CC genotype and response to methotrexate in patients with neoplasms. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to methotrexate.		[ 26]
Platinum Compounds	N.A.	Non-small Cell Lung Carcinoma	Patients with lung cancer and the CC genotype may have an increased progression-free survival time when treated with platinum-based chemotherapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.		[ 27]
Methotrexate	N.A.	Neoplasms	Genotype CC is associated with increased severity of mucositis when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CT + TT.		[ 23]
Methotrexate	N.A.	Neoplasms	The current evidence base suggests that there is no significant association between the rs1051266 CC genotype and risk of drug toxicity when treated with methotrexate in patients with neoplasms. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with methotrexate.		[ 3]
Imatinib	N.A.	Gastrointestinal Stromal Tumors	Patients with the CC genotype and gastrointestinal stromal tumors may have a decreased risk for toxicity when treated with imatinib as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for toxicity in patients receiving imatinib.		[ 29]
Methotrexate	N.A.	Burkitt Lymphoma	The current evidence base suggests that there is no significant association between the rs1051266 CC genotype and methotrexate concentrations in patients with neoplasms. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs1051266 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate concentrations.		[ 26]
Methotrexate	N.A.	Leukemia	The current evidence base suggests that there is no significant association between the rs1051266 CC genotype and methotrexate concentrations in patients with neoplasms. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs1051266 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate concentrations.		[ 26]
Methotrexate	N.A.	Lymphoma, T-cell	The current evidence base suggests that there is no significant association between the rs1051266 CC genotype and methotrexate concentrations in patients with neoplasms. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs1051266 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate concentrations.		[ 26]
Methotrexate	N.A.	Osteosarcoma	The current evidence base suggests that there is no significant association between the rs1051266 CC genotype and methotrexate concentrations in patients with neoplasms. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs1051266 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate concentrations.		[ 26]
Methotrexate	N.A.	Rheumatoid Arthritis	Genotype CC is associated with increased risk of Drug Toxicity when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotypes CT + TT.		[ 21]
Methotrexate	N.A.	Drug Toxicity	Patients with the rs1051266 CC genotype and rheumatoid arthritis may have increased likelihood of toxicity when treated with methotrexate as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence methotrexate toxicity.		[ 10]
Methotrexate	N.A.	Rheumatoid Arthritis	Patients with the rs1051266 CC genotype and rheumatoid arthritis may have increased likelihood of toxicity when treated with methotrexate as compared to patients with the CT or TT genotypes. Other genetic and clinical factors may also influence methotrexate toxicity.		[ 10]
Methotrexate	N.A.	Rheumatoid Arthritis	Patients with the rs1051266 CC genotype and rheumatoid arthritis may have decreased response when treated with methotrexate as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence methotrexate response.		[ 19]
Genotype CT	Click to Show/Hide the Full List of Affected Drugs:         19 Drugs in Total
Methotrexate	Drug Info	Precursor Cell Lymphoblastic Leukemia-Lymphoma	Correlated with the decreased drug response in patients (compare with Genotype TT)		[ 29]
Methotrexate	N.A.	Drug Toxicity	Genotype CT is associated with decreased response to methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.		[ 29]
Methotrexate	N.A.	Toxic Liver Disease	Genotype CT is associated with increased risk of Toxic liver disease due to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.		[ 8]
Irinotecan	N.A.	Colorectal Neoplasms	Patients with the CT genotype and metastatic colorectal cancer may have decreased rapid response to treatment containing irinotecan as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to irinotecan based treatment.		[ 20]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Genotype CT is associated with decreased response to methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.		[ 29]
Methotrexate	N.A.	Neoplasms	Genotype CT is associated with decreased response to methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.		[ 29]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	The current evidence base suggests that there is no significant association between the rs1051266 CT genotype and response to methotrexate in patients with neoplasms. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to methotrexate.		[ 26]
Methotrexate	N.A.	Neoplasms	The current evidence base suggests that there is no significant association between the rs1051266 CT genotype and response to methotrexate in patients with neoplasms. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to methotrexate.		[ 26]
Platinum Compounds	N.A.	Non-small Cell Lung Carcinoma	Patients with lung cancer and the CT genotype may have an increased progression-free survival time when treated with platinum-based chemotherapy as compared to patients with the TT genotype. Other genetic and clinical factors may also influence response to platinum-based chemotherapy.		[ 27]
Methotrexate	N.A.	Neoplasms	Genotype CT is associated with increased risk of Toxic liver disease due to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.		[ 8]
Methotrexate	N.A.	Neoplasms	The current evidence base suggests that there is no significant association between the rs1051266 CT genotype and risk of drug toxicity when treated with methotrexate in patients with neoplasms. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with methotrexate.		[ 3]
Imatinib	N.A.	Gastrointestinal Stromal Tumors	Patients with the CT genotype and gastrointestinal stromal tumors may have a decreased risk for toxicity when treated with imatinib as compared to patients with the TT genotype. Other genetic and clinical factors may also influence risk for toxicity in patients receiving imatinib.		[ 28]
Methotrexate	N.A.	Burkitt Lymphoma	The current evidence base suggests that there is no significant association between the rs1051266 CT genotype and methotrexate concentrations in patients with neoplasms. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs1051266 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate concentrations.		[ 26]
Methotrexate	N.A.	Leukemia	The current evidence base suggests that there is no significant association between the rs1051266 CT genotype and methotrexate concentrations in patients with neoplasms. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs1051266 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate concentrations.		[ 26]
Methotrexate	N.A.	Lymphoma, T-cell	The current evidence base suggests that there is no significant association between the rs1051266 CT genotype and methotrexate concentrations in patients with neoplasms. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs1051266 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate concentrations.		[ 26]
Methotrexate	N.A.	Osteosarcoma	The current evidence base suggests that there is no significant association between the rs1051266 CT genotype and methotrexate concentrations in patients with neoplasms. However, conflicting evidence has been reported. This annotation only covers the pharmacokinetic relationship between rs1051266 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate concentrations.		[ 26]
Methotrexate	N.A.	Drug Toxicity	Patients with the rs1051266 CT genotype and rheumatoid arthritis may have increased likelihood of toxicity when treated with methotrexate as compared to patients with the TT genotype but a decreased likelihood as compared to patients with the CC genotype. Other genetic and clinical factors may also influence methotrexate toxicity.		[ 10]
Methotrexate	N.A.	Rheumatoid Arthritis	Patients with the rs1051266 CT genotype and rheumatoid arthritis may have increased likelihood of toxicity when treated with methotrexate as compared to patients with the TT genotype but a decreased likelihood as compared to patients with the CC genotype. Other genetic and clinical factors may also influence methotrexate toxicity.		[ 10]
Methotrexate	N.A.	Rheumatoid Arthritis	Patients with the rs1051266 CT genotype and rheumatoid arthritis may have decreased response when treated with methotrexate as compared to patients with the TT genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence methotrexate response.		[ 19]
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:         99 Drugs in Total
Methotrexate	Drug Info	Rheumatoid Arthritis	Correlated with the decreased disease activity in patients (compare with genotypes CC + CT); Correlated with the decreased drug response in patients (compare with genotype CC); Correlated with the increased aminotransferase activity in patients (compare with genotypes CC + CT); Correlated with the increased likelihood of remission in patients (compare with genotype CC); Correlated with the increased methotrexate polyglutamate (mtXPG3-5) levels in patients (compare with genotypes CC + CT)		[ 12], [ 19], [ 31], [ 33]
Methotrexate	Drug Info	Precursor Cell Lymphoblastic Leukemia-Lymphoma	Correlated with the increased likelihood of myelosuppression in patients (compare with genotypes CC + CT); Correlated with the increased likelihood of staying in remission in patients (compare with genotypes CC + CT); Correlated with the increased likelihood of toxic liver disease in patients (compare with genotypes CC + CT); Correlated with the increased plasma drug levels in patients (compare with genotypes CC + CT); Irrelevant to the drug concentrations in patients (compare with genotypes CC + CT); Irrelevant to the drug toxicity risk in patients (compare with genotypes CC + CT)		[ 14], [ 22], [ 36], [ 37]
Mercaptopurine	Drug Info	Precursor Cell Lymphoblastic Leukemia-Lymphoma	Correlated with the increased likelihood of staying in remission in patients (compare with genotypes CC + CT)		[ 22]
Leucovorin	Drug Info	Precursor Cell Lymphoblastic Leukemia-Lymphoma	Correlated with the increased likelihood of staying in remission in patients (compare with genotypes CC + CT)		[ 22]
Methotrexate	Drug Info	Osteosarcoma	Correlated with the increased neoplasm metastasis risk in patients (compare with genotypes CC + CT)		[ 24]
Methotrexate	Drug Info	Lymphoma	Correlated with the increased toxic liver disease risk in patients (compare with genotype CC); Irrelevant to the increased drug concentrations in patients (compare with genotype CC)		[ 39]
Prednisone	Drug Info	Rheumatoid Arthritis	Correlated with the increased likelihood of remission in patients (compare with genotype CC)		[ 12]
Methotrexate	N.A.	Drug Toxicity	Genotype TT is not associated with plasma drug concentration when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma.		[ 40]
Methotrexate	N.A.	Drug Toxicity	Genotype TT is associated with increased methotrexate polyglutamate (MTXPG3-5) levels when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotypes CC + CT.		[ 33]
Methotrexate	N.A.	Graft Vs Host Disease	Genotype TT is associated with decreased concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT.		[ 26]
Mercaptopurine	N.A.	Anemia	Genotype TT is associated with increased likelihood of Anemia, Neutropenia, Pancytopenia or Thrombocytopenia when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.		[ 42]
Mercaptopurine	N.A.	Neutropenia	Genotype TT is associated with increased likelihood of Anemia, Neutropenia, Pancytopenia or Thrombocytopenia when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.		[ 42]
Mercaptopurine	N.A.	Pancytopenia	Genotype TT is associated with increased likelihood of Anemia, Neutropenia, Pancytopenia or Thrombocytopenia when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.		[ 42]
Mercaptopurine	N.A.	Thrombocytopenia	Genotype TT is associated with increased likelihood of Anemia, Neutropenia, Pancytopenia or Thrombocytopenia when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.		[ 42]
Methotrexate	N.A.	Drug Toxicity	Genotype TT is associated with increased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotypes CC + CT.		[ 43]
Mirabegron	N.A.	Drug Toxicity	Genotype TT is associated with decreased dose-adjusted trough concentrations of mirabegron in healthy individuals as compared to genotype CT.		[ 44]
Methotrexate	N.A.	Drug Toxicity	Genotype TT is associated with increased clinical benefit to methotrexate in people with Arthritis, Rheumatoid as compared to genotypes CC + CT.		[ 45]
Methotrexate	N.A.	Drug Toxicity	Genotype TT is not associated with increased concentrations of methotrexate in people with Burkitt Lymphoma, Lymphoma, T-Cell and Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.		[ 39]
Methotrexate	N.A.	Metastatic Neoplasm	Genotype TT is associated with increased risk of Neoplasm Metastasis when treated with methotrexate in people with Osteosarcoma as compared to genotypes CC + CT.		[ 24]
Methotrexate	N.A.	Adverse Events	Genotype TT is associated with decreased risk of adverse events due to methotrexate in people with Arthritis, Rheumatoid as compared to genotypes CC + CT.		[ 17]
Methotrexate	N.A.	Mucositis	Genotype TT is associated with increased likelihood of mucositis, Neutropenia, Pancreatitis or Vomiting when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT.		[ 47]
Methotrexate	N.A.	Neutropenia	Genotype TT is associated with increased likelihood of mucositis, Neutropenia, Pancreatitis or Vomiting when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT.		[ 47]
Methotrexate	N.A.	Pancreatitis	Genotype TT is associated with increased likelihood of mucositis, Neutropenia, Pancreatitis or Vomiting when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT.		[ 47]
Methotrexate	N.A.	Vomiting	Genotype TT is associated with increased likelihood of mucositis, Neutropenia, Pancreatitis or Vomiting when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT.		[ 47]
Methotrexate	N.A.	Drug Toxicity	Genotype TT is associated with decreased disease activity as assessed by the physician, less patient-assessed difficulty with physical tasks, and fewer swollen joints when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotypes CC + CT.		[ 31]
Methotrexate	N.A.	Drug Toxicity	Genotype TT is not associated with risk of Drug Toxicity when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT.		[ 37]
Methotrexate	N.A.	Drug Toxicity	Genotype TT is not associated with concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT.		[ 37]
Methotrexate	N.A.	Toxic Liver Disease	Genotype TT is associated with increased likelihood of Toxic liver disease when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT.		[ 48]
Methotrexate	N.A.	Gastrointestinal Toxicity	Genotype TT is associated with increased steady-state concentration of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT.		[ 49]
Methotrexate	N.A.	Toxic Liver Disease	Genotype TT is associated with increased risk of Toxic liver disease due to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT.		[ 49]
Methotrexate	N.A.	Toxic Liver Disease	Genotype TT is associated with increased risk of Toxic liver disease when treated with methotrexate in people with Burkitt Lymphoma, Lymphoma, T-Cell and Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.		[ 39]
Imatinib	N.A.	Drug Toxicity	Genotype TT is associated with increased risk of Drug Toxicity when treated with imatinib in people with Gastrointestinal Stromal Tumors as compared to genotypes CC + CT.		[ 28]
Methotrexate	N.A.	Toxic Liver Disease	Genotype TT is associated with increased plasma drug levels when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT.		[ 14]
Methotrexate	N.A.	Toxic Liver Disease	Genotype TT is associated with increased likelihood of Toxic liver disease when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT.		[ 36]
Methotrexate	N.A.	Toxic Liver Disease	Genotype TT is associated with increased plasma drug levels of methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT.		[ 22]
Leucovorin	N.A.	Myelosuppression	Genotype TT is associated with increased likelihood of Myelosuppression when treated with leucovorin, mercaptopurine and methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT.		[ 22]
Mercaptopurine	N.A.	Myelosuppression	Genotype TT is associated with increased likelihood of Myelosuppression when treated with leucovorin, mercaptopurine and methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT.		[ 22]
Methotrexate	N.A.	Myelosuppression	Genotype TT is associated with increased likelihood of Myelosuppression when treated with leucovorin, mercaptopurine and methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT.		[ 22]
Leucovorin	N.A.	Myelosuppression	Genotype TT is associated with increased likelihood of staying in remission when treated with leucovorin, mercaptopurine and methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT.		[ 22]
Mercaptopurine	N.A.	Myelosuppression	Genotype TT is associated with increased likelihood of staying in remission when treated with leucovorin, mercaptopurine and methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT.		[ 22]
Platinum Compounds	N.A.	Progression-free Survival	Genotype TT is associated with decreased progression-free survival when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes CC + CT.		[ 27]
Methotrexate	N.A.	Progression-free Survival	Genotype TT is associated with increased aminotransferase activity when treated with methotrexate and prednisone in people with Arthritis, Rheumatoid as compared to genotypes CC + CT.		[ 12]
Prednisone	N.A.	Progression-free Survival	Genotype TT is associated with increased aminotransferase activity when treated with methotrexate and prednisone in people with Arthritis, Rheumatoid as compared to genotypes CC + CT.		[ 12]
Irinotecan	N.A.	Colorectal Neoplasms	Patients with the TT genotype and metastatic colorectal cancer may have decreased rapid response to treatment containing irinotecan as compared to patients with the CC genotype. Other genetic and clinical factors may also influence a patient's response to irinotecan based treatment.		[ 20]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	The current evidence base suggests that there is no significant association between the rs1051266 TT genotype and response to methotrexate in patients with neoplasms. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to methotrexate.		[ 26]
Methotrexate	N.A.	Neoplasms	The current evidence base suggests that there is no significant association between the rs1051266 TT genotype and response to methotrexate in patients with neoplasms. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence response to methotrexate.		[ 26]
Platinum Compounds	N.A.	Non-small Cell Lung Carcinoma	Genotype TT is associated with decreased progression-free survival when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes CC + CT.		[ 27]
Methotrexate	N.A.	Neoplasms	Genotype TT is associated with increased risk of Toxic liver disease due to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT.		[ 49]
Methotrexate	N.A.	Neoplasms	Genotype TT is associated with increased likelihood of Toxic liver disease when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT.		[ 36]
Methotrexate	N.A.	Neoplasms	Genotype TT is associated with increased risk of Toxic liver disease when treated with methotrexate in people with Burkitt Lymphoma, Lymphoma, T-Cell and Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.		[ 39]
Methotrexate	N.A.	Neoplasms	Genotype TT is not associated with risk of Drug Toxicity when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT.		[ 37]
Methotrexate	N.A.	Neoplasms	The current evidence base suggests that there is no significant association between the rs1051266 TT genotype and risk of drug toxicity when treated with methotrexate in patients with neoplasms. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence risk of drug toxicity when treated with methotrexate.		[ 3]
Imatinib	N.A.	Gastrointestinal Stromal Tumors	Genotype TT is associated with increased risk of Drug Toxicity when treated with imatinib in people with Gastrointestinal Stromal Tumors as compared to genotypes CC + CT.		[ 28]
Methotrexate	N.A.	Burkitt Lymphoma	Genotype TT is associated with decreased concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT.		[ 26]
Methotrexate	N.A.	Leukemia	Genotype TT is associated with decreased concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT.		[ 26]
Methotrexate	N.A.	Lymphoma, T-cell	Genotype TT is associated with decreased concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT.		[ 26]
Methotrexate	N.A.	Osteosarcoma	Genotype TT is associated with decreased concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT.		[ 26]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Genotype TT is associated with increased steady-state concentration of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT.		[ 49]
Methotrexate	N.A.	Burkitt Lymphoma	Genotype TT is associated with increased steady-state concentration of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT.		[ 49]
Methotrexate	N.A.	Leukemia	Genotype TT is associated with increased steady-state concentration of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT.		[ 49]
Methotrexate	N.A.	Lymphoma, T-cell	Genotype TT is associated with increased steady-state concentration of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT.		[ 49]
Methotrexate	N.A.	Osteosarcoma	Genotype TT is associated with increased steady-state concentration of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT.		[ 49]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Genotype TT is associated with increased plasma drug levels when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT.		[ 14]
Methotrexate	N.A.	Burkitt Lymphoma	Genotype TT is associated with increased plasma drug levels when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT.		[ 14]
Methotrexate	N.A.	Leukemia	Genotype TT is associated with increased plasma drug levels when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT.		[ 14]
Methotrexate	N.A.	Lymphoma, T-cell	Genotype TT is associated with increased plasma drug levels when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT.		[ 14]
Methotrexate	N.A.	Neoplasms	Genotype TT is associated with increased plasma drug levels when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT.		[ 14]
Methotrexate	N.A.	Osteosarcoma	Genotype TT is associated with increased plasma drug levels when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT.		[ 14]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Genotype TT is not associated with plasma drug concentration when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma.		[ 40]
Methotrexate	N.A.	Burkitt Lymphoma	Genotype TT is not associated with plasma drug concentration when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma.		[ 40]
Methotrexate	N.A.	Leukemia	Genotype TT is not associated with plasma drug concentration when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma.		[ 40]
Methotrexate	N.A.	Lymphoma, T-cell	Genotype TT is not associated with plasma drug concentration when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma.		[ 40]
Methotrexate	N.A.	Neoplasms	Genotype TT is not associated with plasma drug concentration when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma.		[ 40]
Methotrexate	N.A.	Osteosarcoma	Genotype TT is not associated with plasma drug concentration when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma.		[ 40]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Genotype TT is associated with increased plasma drug levels of methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT.		[ 22]
Methotrexate	N.A.	Burkitt Lymphoma	Genotype TT is associated with increased plasma drug levels of methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT.		[ 22]
Methotrexate	N.A.	Leukemia	Genotype TT is associated with increased plasma drug levels of methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT.		[ 22]
Methotrexate	N.A.	Lymphoma, T-cell	Genotype TT is associated with increased plasma drug levels of methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT.		[ 22]
Methotrexate	N.A.	Neoplasms	Genotype TT is associated with increased plasma drug levels of methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT.		[ 22]
Methotrexate	N.A.	Osteosarcoma	Genotype TT is associated with increased plasma drug levels of methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT.		[ 22]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Genotype TT is not associated with increased concentrations of methotrexate in people with Burkitt Lymphoma, Lymphoma, T-Cell and Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.		[ 39]
Methotrexate	N.A.	Burkitt Lymphoma	Genotype TT is not associated with increased concentrations of methotrexate in people with Burkitt Lymphoma, Lymphoma, T-Cell and Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.		[ 39]
Methotrexate	N.A.	Leukemia	Genotype TT is not associated with increased concentrations of methotrexate in people with Burkitt Lymphoma, Lymphoma, T-Cell and Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.		[ 39]
Methotrexate	N.A.	Lymphoma, T-cell	Genotype TT is not associated with increased concentrations of methotrexate in people with Burkitt Lymphoma, Lymphoma, T-Cell and Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.		[ 39]
Methotrexate	N.A.	Osteosarcoma	Genotype TT is not associated with increased concentrations of methotrexate in people with Burkitt Lymphoma, Lymphoma, T-Cell and Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.		[ 39]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Genotype TT is not associated with concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT.		[ 37]
Methotrexate	N.A.	Burkitt Lymphoma	Genotype TT is not associated with concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT.		[ 37]
Methotrexate	N.A.	Leukemia	Genotype TT is not associated with concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT.		[ 37]
Methotrexate	N.A.	Lymphoma, T-cell	Genotype TT is not associated with concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT.		[ 37]
Methotrexate	N.A.	Osteosarcoma	Genotype TT is not associated with concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes CC + CT.		[ 37]
Methotrexate	N.A.	Drug Toxicity	Genotype TT is associated with decreased risk of adverse events due to methotrexate in people with Arthritis, Rheumatoid as compared to genotypes CC + CT.		[ 17]
Methotrexate	N.A.	Rheumatoid Arthritis	Genotype TT is associated with decreased risk of adverse events due to methotrexate in people with Arthritis, Rheumatoid as compared to genotypes CC + CT.		[ 17]
Methotrexate	N.A.	Drug Toxicity	Patients with the rs1051266 TT genotype and rheumatoid arthritis may have decreased likelihood of toxicity when treated with methotrexate as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence methotrexate toxicity.		[ 10]
Methotrexate	N.A.	Rheumatoid Arthritis	Patients with the rs1051266 TT genotype and rheumatoid arthritis may have decreased likelihood of toxicity when treated with methotrexate as compared to patients with the CC or CT genotypes. Other genetic and clinical factors may also influence methotrexate toxicity.		[ 10]
Methotrexate	N.A.	Rheumatoid Arthritis	Genotype TT is associated with decreased disease activity as assessed by the physician, less patient-assessed difficulty with physical tasks, and fewer swollen joints when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotypes CC + CT.		[ 31]
Methotrexate	N.A.	Rheumatoid Arthritis	Genotype TT is associated with increased likelihood of remission when treated with methotrexate and prednisone in people with Arthritis, Rheumatoid as compared to genotype CC.		[ 12]
Methotrexate	N.A.	Rheumatoid Arthritis	Genotype TT is associated with increased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotypes CC + CT.		[ 43]
Methotrexate	N.A.	Rheumatoid Arthritis	Patients with the rs1051266 TT genotype and rheumatoid arthritis may have increased response when treated with methotrexate as compared to patients with the CC genotype. However, conflicting evidence has been reported. Other genetic and clinical factors may also influence methotrexate response.		[ 19]
Platinum compounds	N.A.	Non-Small-Cell Lung Carcinoma	Correlated with the decreased progression-free survival in patients (compare with genotypes CC + CT)		[ 27]
Genotypes CC + CT	Click to Show/Hide the Full List of Affected Drugs:           9 Drugs in Total
Methotrexate	Drug Info	Rheumatoid Arthritis	Correlated with the increased gastrointestinal toxicity risk in patients (compare with Genotype TT); Correlated with the increased severity of disease in patients (compare with Genotype TT)		[ 43], [ 44]
Methotrexate	Drug Info	Precursor Cell Lymphoblastic Leukemia-Lymphoma	Irrelevant to the mucositis risk in patients (compare with Genotype TT)		[ 1]
Methotrexate	N.A.	Rheumatoid Arthritis	Genotypes CC + CT are associated with increased severity of Arthritis, Rheumatoid when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotype TT.		[ 44]
Methotrexate	N.A.	Drug Toxicity	Genotypes CC + CT is associated with increased likelihood of Drug Toxicity when treated with methotrexate in children with Acute lymphoblastic leukemia as compared to genotype TT.		[ 46]
Methotrexate	N.A.	Gastrointestinal Toxicity	Genotypes CC + CT is associated with increased risk of gastrointestinal toxicity when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotype TT.		[ 43]
Methotrexate	N.A.	Mucositis	Genotypes CC + CT are not associated with risk of mucositis when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.		[ 1]
Methotrexate	N.A.	Neoplasms	Genotypes CC + CT are not associated with risk of mucositis when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT.		[ 1]
Methotrexate	N.A.	Drug Toxicity	Genotypes CC + CT is associated with increased risk of gastrointestinal toxicity when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotype TT.		[ 43]
Methotrexate	N.A.	Rheumatoid Arthritis	Genotypes CC + CT is associated with increased risk of gastrointestinal toxicity when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotype TT.		[ 43]
Genotypes CT + TT	Click to Show/Hide the Full List of Affected Drugs:         28 Drugs in Total
Methotrexate	Drug Info	Rheumatoid Arthritis	Correlated with the decreased drug discontinuation in patients (compare with genotype CC); Correlated with the increased drug response in patients (compare with genotype CC)		[ 46], [ 47]
Mercaptopurine	Drug Info	Precursor Cell Lymphoblastic Leukemia-Lymphoma	Correlated with the increased drug toxicity risk in patients (compare with genotype CC)		[ 48]
Methotrexate	Drug Info	Precursor Cell Lymphoblastic Leukemia-Lymphoma	Correlated with the increased drug toxicity risk in patients (compare with genotype CC); Irrelevant to the drug concentrations in patients (compare with genotype CC)		[ 1], [ 48]
Methotrexate	N.A.	Thrombocytopenia	Genotypes CT + TT are not associated with concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.		[ 1]
Mercaptopurine	N.A.	Drug Toxicity	Genotypes CT + TT are associated with increased risk of Drug Toxicity when treated with mercaptopurine and methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.		[ 48]
Methotrexate	N.A.	Drug Toxicity	Genotypes CT + TT are associated with increased risk of Drug Toxicity when treated with mercaptopurine and methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.		[ 48]
Methotrexate	N.A.	Drug Toxicity	Genotypes CT + TT is associated with decreased discontinuation of methotrexate in people with Arthritis, Rheumatoid as compared to genotype CC.		[ 46]
Methotrexate	N.A.	Mucositis	Genotypes CT + TT are associated with decreased risk of mucositis due to methotrexate in children with Osteosarcoma as compared to genotype CC.		[ 50]
Methotrexate	N.A.	Drug Toxicity	Genotypes CT + TT is associated with increased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype CC.		[ 47]
Methotrexate	N.A.	Nausea	Genotypes CT + TT are associated with decreased concentrations of methotrexate in children with Osteosarcoma as compared to genotype CC.		[ 50]
Mercaptopurine	N.A.	Toxic Liver Disease	Genotypes CT + TT are associated with increased likelihood of treatment interruptions when treated with mercaptopurine in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.		[ 51]
Mercaptopurine	N.A.	Drug Toxicity	Genotypes CT + TT are associated with increased likelihood of Drug Toxicity when treated with mercaptopurine and methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.		[ 35]
Methotrexate	N.A.	Drug Toxicity	Genotypes CT + TT are associated with increased likelihood of Drug Toxicity when treated with mercaptopurine and methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.		[ 35]
Methotrexate	N.A.	Neoplasms	Genotypes CT + TT are associated with decreased risk of mucositis due to methotrexate in children with Osteosarcoma as compared to genotype CC.		[ 50]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Genotypes CT + TT are associated with decreased concentrations of methotrexate in children with Osteosarcoma as compared to genotype CC.		[ 50]
Methotrexate	N.A.	Burkitt Lymphoma	Genotypes CT + TT are associated with decreased concentrations of methotrexate in children with Osteosarcoma as compared to genotype CC.		[ 50]
Methotrexate	N.A.	Leukemia	Genotypes CT + TT are associated with decreased concentrations of methotrexate in children with Osteosarcoma as compared to genotype CC.		[ 50]
Methotrexate	N.A.	Lymphoma, T-cell	Genotypes CT + TT are associated with decreased concentrations of methotrexate in children with Osteosarcoma as compared to genotype CC.		[ 50]
Methotrexate	N.A.	Osteosarcoma	Genotypes CT + TT are associated with decreased concentrations of methotrexate in children with Osteosarcoma as compared to genotype CC.		[ 50]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Genotypes CT + TT are not associated with concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.		[ 1]
Methotrexate	N.A.	Burkitt Lymphoma	Genotypes CT + TT are not associated with concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.		[ 1]
Methotrexate	N.A.	Leukemia	Genotypes CT + TT are not associated with concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.		[ 1]
Methotrexate	N.A.	Lymphoma, T-cell	Genotypes CT + TT are not associated with concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.		[ 1]
Methotrexate	N.A.	Neoplasms	Genotypes CT + TT are not associated with concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.		[ 1]
Methotrexate	N.A.	Osteosarcoma	Genotypes CT + TT are not associated with concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC.		[ 1]
Methotrexate	N.A.	Drug Toxicity	Genotypes CT + TT is associated with decreased discontinuation of methotrexate in people with Arthritis, Rheumatoid as compared to genotype CC.		[ 46]
Methotrexate	N.A.	Rheumatoid Arthritis	Genotypes CT + TT is associated with decreased discontinuation of methotrexate in people with Arthritis, Rheumatoid as compared to genotype CC.		[ 46]
Methotrexate	N.A.	Rheumatoid Arthritis	Genotypes CT + TT is associated with increased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype CC.		[ 47]
Genotypes TT + CT	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Methotrexate	Drug Info	Precursor Cell Lymphoblastic Leukemia-Lymphoma	Correlated with the increased likelihood of drug toxicity in patients (compare with genotype CC)		[ 35]
Mercaptopurine	Drug Info	Precursor Cell Lymphoblastic Leukemia-Lymphoma	Correlated with the increased likelihood of drug toxicity in patients (compare with genotype CC); Correlated with the increased likelihood of treatment interruptions in patients (compare with genotype CC)		[ 35], [ 50]
Genotypes CC + TT	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Methotrexate	N.A.	Graft Vs Host Disease	Genotypes CC + TT are associated with decreased response to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CT.		[ 26]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Genotypes CC + TT are associated with decreased response to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CT.		[ 26]
Methotrexate	N.A.	Neoplasms	Genotypes CC + TT are associated with decreased response to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CT.		[ 26]
Genetic Polymorphism	rs1051298
Site of GPD	chr21:45514912 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A
Minor Allele Frequency	G=0.4756/2382 (Global)
Allele G	Click to Show/Hide the Full List of Affected Drugs:           6 Drugs in Total
Pemetrexed	Drug Info	Lung Neoplasm	Correlated with the increased progression-free survival in patients (compare with Allele A)		[ 51]
Bevacizumab	N.A.	Progression-free Survival	Allele G is associated with increased progression-free survival when treated with bevacizumab and pemetrexed in people with Lung Neoplasms as compared to allele A.		[ 51]
Pemetrexed	N.A.	Progression-free Survival	Allele G is associated with increased progression-free survival when treated with bevacizumab and pemetrexed in people with Lung Neoplasms as compared to allele A.		[ 51]
Pemetrexed	N.A.	Mesothelioma	Allele G is associated with increased progression-free survival when treated with bevacizumab and pemetrexed in people with Lung Neoplasms as compared to allele A.		[ 51]
Pemetrexed	N.A.	Non-small Cell Lung Carcinoma	Allele G is associated with increased progression-free survival when treated with bevacizumab and pemetrexed in people with Lung Neoplasms as compared to allele A.		[ 51]
Bevacizumab	N.A.	Lung Neoplasm	Correlated with the increased progression-free survival in patients (compare with Allele A)		[ 51]
Genotypes AA + AG	Click to Show/Hide the Full List of Affected Drugs:           4 Drugs in Total
Pemetrexed	Drug Info	Non-Small-Cell Lung Carcinoma	Correlated with the decreased overall survival in patients (compare with genotype GG)		[ 52]
Pemetrexed	N.A.	Overall Survival	Genotypes AA + AG is associated with decreased overall survival when treated with pemetrexed in people with Carcinoma, Non-Small-Cell Lung and Mesothelioma as compared to genotype GG.		[ 52]
Pemetrexed	N.A.	Mesothelioma	Genotypes AA + AG is associated with decreased overall survival when treated with pemetrexed in people with Carcinoma, Non-Small-Cell Lung and Mesothelioma as compared to genotype GG.		[ 52]
Pemetrexed	N.A.	Non-small Cell Lung Carcinoma	Genotypes AA + AG is associated with decreased overall survival when treated with pemetrexed in people with Carcinoma, Non-Small-Cell Lung and Mesothelioma as compared to genotype GG.		[ 52]
Genotype AA	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Pemetrexed	N.A.	Mesothelioma	Patients with the AA genotype and lung cancer may have shorter overall and progression-free survival times when treated with pemetrexed as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence survival time.		[ 51]
Pemetrexed	N.A.	Non-small Cell Lung Carcinoma	Patients with the AA genotype and lung cancer may have shorter overall and progression-free survival times when treated with pemetrexed as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence survival time.		[ 51]
Genotype AG	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Pemetrexed	N.A.	Mesothelioma	Patients with the AG genotype and lung cancer may have shorter overall and progression-free survival times when treated with pemetrexed as compared to patients with the GG genotype, and a longer overall survival time as compared to patients with the AA genotype. Other genetic and clinical factors may also influence survival time.		[ 51]
Pemetrexed	N.A.	Non-small Cell Lung Carcinoma	Patients with the AG genotype and lung cancer may have shorter overall and progression-free survival times when treated with pemetrexed as compared to patients with the GG genotype, and a longer overall survival time as compared to patients with the AA genotype. Other genetic and clinical factors may also influence survival time.		[ 51]
Genotype GG	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Pemetrexed	N.A.	Mesothelioma	Patients with the GG genotype and lung cancer may have longer overall and progression-free survival times when treated with pemetrexed as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence survival time.		[ 51]
Pemetrexed	N.A.	Non-small Cell Lung Carcinoma	Patients with the GG genotype and lung cancer may have longer overall and progression-free survival times when treated with pemetrexed as compared to patients with the AA or AG genotype. Other genetic and clinical factors may also influence survival time.		[ 51]
Genetic Polymorphism	rs12659
Site of GPD	chr21:45531642 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	A>G
Minor Allele Frequency	A=0.4469/2238 (Global)
Allele A	Click to Show/Hide the Full List of Affected Drugs:           9 Drugs in Total
Fluorouracil	Drug Info	Uterine Cervical Neoplasm	Correlated with the decreased drug response in patients (compare with allele G)		[ 53]
Cisplatin	Drug Info	Uterine Cervical Neoplasm	Correlated with the decreased drug response in patients (compare with allele G)		[ 53]
Carboplatin	Drug Info	Uterine Cervical Neoplasm	Correlated with the decreased drug response in patients (compare with allele G)		[ 53]
Carboplatin	N.A.	Progression-free Survival	Allele A is associated with decreased response to carboplatin, cisplatin and fluorouracil in people with Uterine Cervical Neoplasms as compared to allele G.		[ 53]
Cisplatin	N.A.	Progression-free Survival	Allele A is associated with decreased response to carboplatin, cisplatin and fluorouracil in people with Uterine Cervical Neoplasms as compared to allele G.		[ 53]
Fluorouracil	N.A.	Progression-free Survival	Allele A is associated with decreased response to carboplatin, cisplatin and fluorouracil in people with Uterine Cervical Neoplasms as compared to allele G.		[ 53]
Carboplatin	N.A.	Uterine Cervical Neoplasm	Allele A is associated with decreased response to carboplatin, cisplatin and fluorouracil in people with Uterine Cervical Neoplasms as compared to allele G.		[ 53]
Cisplatin	N.A.	Uterine Cervical Neoplasm	Allele A is associated with decreased response to carboplatin, cisplatin and fluorouracil in people with Uterine Cervical Neoplasms as compared to allele G.		[ 53]
Fluorouracil	N.A.	Uterine Cervical Neoplasm	Allele A is associated with decreased response to carboplatin, cisplatin and fluorouracil in people with Uterine Cervical Neoplasms as compared to allele G.		[ 53]
Genotypes AG + GG	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Imatinib	N.A.	Drug Toxicity	Genotypes AG + GG is associated with decreased risk of Drug Toxicity when treated with imatinib in people with Gastrointestinal Stromal Tumors as compared to genotype AA.		[ 28]
Imatinib	N.A.	Gastrointestinal Stromal Tumors	Genotypes AG + GG is associated with decreased risk of Drug Toxicity when treated with imatinib in people with Gastrointestinal Stromal Tumors as compared to genotype AA.		[ 28]
Genotype AA	Click to Show/Hide the Full List of Affected Drugs:           4 Drugs in Total
Carboplatin	N.A.	Uterine Cervical Neoplasm	Patients with the AA genotype and cervical cancer who are treated with carboplatin, cisplatin and fluorouracil may have a reduced response to treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to platinum-based neoadjuvant treatment.		[ 53]
Cisplatin	N.A.	Uterine Cervical Neoplasm	Patients with the AA genotype and cervical cancer who are treated with carboplatin, cisplatin and fluorouracil may have a reduced response to treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to platinum-based neoadjuvant treatment.		[ 53]
Fluorouracil	N.A.	Uterine Cervical Neoplasm	Patients with the AA genotype and cervical cancer who are treated with carboplatin, cisplatin and fluorouracil may have a reduced response to treatment as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's response to platinum-based neoadjuvant treatment.		[ 53]
Imatinib	N.A.	Gastrointestinal Stromal Tumors	Patients with the AA genotype and gastrointestinal stromal tumors may have an increased risk for toxicity when treated with imatinib as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence risk for toxicity in patients receiving imatinib.		[ 28]
Genotype AG	Click to Show/Hide the Full List of Affected Drugs:           4 Drugs in Total
Carboplatin	N.A.	Uterine Cervical Neoplasm	Patients with the AG genotype and cervical cancer who are treated with carboplatin, cisplatin and fluorouracil may have a reduced response to treatment as compared to patients with the GG genotype or may have a better response to treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to platinum-based neoadjuvant treatment.		[ 53]
Cisplatin	N.A.	Uterine Cervical Neoplasm	Patients with the AG genotype and cervical cancer who are treated with carboplatin, cisplatin and fluorouracil may have a reduced response to treatment as compared to patients with the GG genotype or may have a better response to treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to platinum-based neoadjuvant treatment.		[ 53]
Fluorouracil	N.A.	Uterine Cervical Neoplasm	Patients with the AG genotype and cervical cancer who are treated with carboplatin, cisplatin and fluorouracil may have a reduced response to treatment as compared to patients with the GG genotype or may have a better response to treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to platinum-based neoadjuvant treatment.		[ 53]
Imatinib	N.A.	Gastrointestinal Stromal Tumors	Patients with the AG genotype and gastrointestinal stromal tumors may have a decreased risk for toxicity when treated with imatinib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for toxicity in patients receiving imatinib.		[ 28]
Genotype GG	Click to Show/Hide the Full List of Affected Drugs:           4 Drugs in Total
Carboplatin	N.A.	Uterine Cervical Neoplasm	Patients with the GG genotype and cervical cancer who are treated with carboplatin, cisplatin and fluorouracil may have a better response to treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to platinum-based neoadjuvant treatment.		[ 53]
Cisplatin	N.A.	Uterine Cervical Neoplasm	Patients with the GG genotype and cervical cancer who are treated with carboplatin, cisplatin and fluorouracil may have a better response to treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to platinum-based neoadjuvant treatment.		[ 53]
Fluorouracil	N.A.	Uterine Cervical Neoplasm	Patients with the GG genotype and cervical cancer who are treated with carboplatin, cisplatin and fluorouracil may have a better response to treatment as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to platinum-based neoadjuvant treatment.		[ 53]
Imatinib	N.A.	Gastrointestinal Stromal Tumors	Patients with the GG genotype and gastrointestinal stromal tumors may have a decreased risk for toxicity when treated with imatinib as compared to patients with the AA genotype. Other genetic and clinical factors may also influence risk for toxicity in patients receiving imatinib.		[ 28]
Genetic Polymorphism	rs2838958
Site of GPD	chr21:45528653 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A
Minor Allele Frequency	A=0.4173/2090 (Global)
Genotype AA	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Methotrexate	Drug Info	Precursor Cell Lymphoblastic Leukemia-Lymphoma	Correlated with the decreased drug response in patients (compare with genotypes AG + GG)		[ 1]
Methotrexate	N.A.	Drug Toxicity	Genotype AA is associated with decreased response to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AG + GG.		[ 1]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Genotype AA is associated with decreased response to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AG + GG.		[ 1]
Genotypes AG + GG	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Methotrexate	N.A.	Thrombocytopenia	Genotypes AG + GG are not associated with concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype AA.		[ 1]
Methotrexate	N.A.	Mucositis	Genotypes AG + GG are not associated with risk of mucositis when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype AA.		[ 1]
Genotypes AA + AG	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Methotrexate	N.A.	Drug Toxicity	Genotypes AA + AG is associated with increased concentrations of methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.		[ 54]
Allele A	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Methotrexate	N.A.	Drug Toxicity	Allele A is associated with decreased clearance of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G.		[ 55]
Genotype AG	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Pediatric patients with precursor cell lymphoblastic leukemia-lymphoma and the AG genotype may have improved response to methotrexate as compared to patients with the AA genotype. Other clinical and genetic factors may also influence response to methotrexate in pediatric patients with precursor cell lymphoblastic leukemia-lymphoma.		[ 1]
Genotype GG	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Pediatric patients with precursor cell lymphoblastic leukemia-lymphoma and the GG genotype may have improved response to methotrexate as compared to patients with the AA genotype. Other clinical and genetic factors may also influence response to methotrexate in pediatric patients with precursor cell lymphoblastic leukemia-lymphoma.		[ 1]
Genetic Polymorphism	rs9977268
Site of GPD	chr21:45487373 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>T
Minor Allele Frequency	T=0.1587/795 (Global)
Allele T	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Methotrexate	Drug Info	Rheumatoid Arthritis	Correlated with the increased likelihood of treatment inefficacy in patients (compare with allele C)		[ 13]
Methotrexate	N.A.	Drug Toxicity	Allele T is associated with increased likelihood of treatment inefficacy when treated with methotrexate in people with Arthritis, Rheumatoid as compared to allele C.		[ 13]
Methotrexate	N.A.	Rheumatoid Arthritis	Allele T is associated with increased likelihood of treatment inefficacy when treated with methotrexate in people with Arthritis, Rheumatoid as compared to allele C.		[ 13]
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Methotrexate	N.A.	Rheumatoid Arthritis	Patients with the CC genotype and Rheumatoid Arthritis who are treated with methotrexate may have an increased likelihood of treatment being effective as compared to patients with the TT genotype. This association was not statistically significant after Bonferroni correction. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.		[ 13]
Genotype CT	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Methotrexate	N.A.	Rheumatoid Arthritis	Patients with the CT genotype and Rheumatoid Arthritis who are treated with methotrexate may have an increased likelihood of treatment being ineffective as compared to patients with the CC genotype or may have an increased likelihood of treatment being effective as compared to patients with the TT genotype. This association was not statistically significant after Bonferroni correction. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.		[ 13]
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Methotrexate	N.A.	Rheumatoid Arthritis	Patients with the TT genotype and Rheumatoid Arthritis who are treated with methotrexate may have increased likelihood of treatment being ineffective as compared to patients with the CC genotype. This association was not statistically significant after Bonferroni correction. Other genetic and clinical factors may also influence a patient's response to methotrexate treatment.		[ 13]
Genetic Polymorphism	rs3788189
Site of GPD	chr21:45516669 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>G
Minor Allele Frequency	T=0.4491/2249 (Global)
Genotypes GG + GT	Click to Show/Hide the Full List of Affected Drugs:           4 Drugs in Total
Pemetrexed	Drug Info	Non-Small-Cell Lung Carcinoma	Correlated with the decreased overall survival in patients (compare with Genotype TT)		[ 52]
Pemetrexed	N.A.	Overall Survival	Genotypes GG + GT is associated with decreased overall survival when treated with pemetrexed in people with Carcinoma, Non-Small-Cell Lung and Mesothelioma as compared to genotype TT.		[ 52]
Pemetrexed	N.A.	Mesothelioma	Genotypes GG + GT is associated with decreased overall survival when treated with pemetrexed in people with Carcinoma, Non-Small-Cell Lung and Mesothelioma as compared to genotype TT.		[ 52]
Pemetrexed	N.A.	Non-small Cell Lung Carcinoma	Genotypes GG + GT is associated with decreased overall survival when treated with pemetrexed in people with Carcinoma, Non-Small-Cell Lung and Mesothelioma as compared to genotype TT.		[ 52]
Genotype GG	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Pemetrexed	N.A.	Mesothelioma	Patients with the GG genotype and lung cancer may have a shorter overall survival time when treated with pemetrexed as compared to patients with the TT genotype. Other genetic and clinical factors may also influence overall survival time.		[ 52]
Pemetrexed	N.A.	Non-small Cell Lung Carcinoma	Patients with the GG genotype and lung cancer may have a shorter overall survival time when treated with pemetrexed as compared to patients with the TT genotype. Other genetic and clinical factors may also influence overall survival time.		[ 52]
Genotype GT	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Pemetrexed	N.A.	Mesothelioma	Patients with the GT genotype and lung cancer may have a shorter overall survival time when treated with pemetrexed as compared to patients with the TT genotype. Other genetic and clinical factors may also influence overall survival time.		[ 52]
Pemetrexed	N.A.	Non-small Cell Lung Carcinoma	Patients with the GT genotype and lung cancer may have a shorter overall survival time when treated with pemetrexed as compared to patients with the TT genotype. Other genetic and clinical factors may also influence overall survival time.		[ 52]
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Pemetrexed	N.A.	Mesothelioma	Patients with the TT genotype and lung cancer may have a longer overall survival time when treated with pemetrexed as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence overall survival time.		[ 52]
Pemetrexed	N.A.	Non-small Cell Lung Carcinoma	Patients with the TT genotype and lung cancer may have a longer overall survival time when treated with pemetrexed as compared to patients with the GG or GT genotype. Other genetic and clinical factors may also influence overall survival time.		[ 52]
Genetic Polymorphism	rs914232
Site of GPD	chr21:45532836 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>C
Minor Allele Frequency	T=0.4936/2472 (Global)
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:           4 Drugs in Total
Pemetrexed	Drug Info	Non-Small-Cell Lung Carcinoma	Correlated with the decreased overall survival in patients (compare with genotypes CC + CT)		[ 52]
Pemetrexed	N.A.	Overall Survival	Genotype TT is associated with decreased overall survival when treated with pemetrexed in people with Carcinoma, Non-Small-Cell Lung and Mesothelioma as compared to genotypes CC + CT.		[ 52]
Pemetrexed	N.A.	Mesothelioma	Genotype TT is associated with decreased overall survival when treated with pemetrexed in people with Carcinoma, Non-Small-Cell Lung and Mesothelioma as compared to genotypes CC + CT.		[ 52]
Pemetrexed	N.A.	Non-small Cell Lung Carcinoma	Genotype TT is associated with decreased overall survival when treated with pemetrexed in people with Carcinoma, Non-Small-Cell Lung and Mesothelioma as compared to genotypes CC + CT.		[ 52]
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Pemetrexed	N.A.	Mesothelioma	Patients with the CC genotype and lung cancer may have a longer overall survival time when treated with pemetrexed as compared to patients with the TT genotype. Other genetic and clinical factors may also influence overall survival time.		[ 52]
Pemetrexed	N.A.	Non-small Cell Lung Carcinoma	Patients with the CC genotype and lung cancer may have a longer overall survival time when treated with pemetrexed as compared to patients with the TT genotype. Other genetic and clinical factors may also influence overall survival time.		[ 52]
Genotype CT	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Pemetrexed	N.A.	Mesothelioma	Patients with the CT genotype and lung cancer may have a longer overall survival time when treated with pemetrexed as compared to patients with the TT genotype. Other genetic and clinical factors may also influence overall survival time.		[ 52]
Pemetrexed	N.A.	Non-small Cell Lung Carcinoma	Patients with the CT genotype and lung cancer may have a longer overall survival time when treated with pemetrexed as compared to patients with the TT genotype. Other genetic and clinical factors may also influence overall survival time.		[ 52]
Genetic Polymorphism	rs4818789
Site of GPD	chr21:45528913 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A / G>C / G>T
Minor Allele Frequency	G=0.1840/364 (Global)
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Cyclosporine	N.A.	Graft Vs Host Disease	Genotype TT is associated with decreased risk of Graft vs Host Disease when treated with cyclosporine and methotrexate in people with Hematopoietic stem cell transplantation as compared to genotypes GG + GT.		[ 25]
Methotrexate	N.A.	Graft Vs Host Disease	Genotype TT is associated with decreased risk of Graft vs Host Disease when treated with cyclosporine and methotrexate in people with Hematopoietic stem cell transplantation as compared to genotypes GG + GT.		[ 25]
Genetic Polymorphism	rs4819128
Site of GPD	chr21:45529735 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>G / C>T
Minor Allele Frequency	C=0.5210/1031 (Global)
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Cyclosporine	N.A.	Graft Vs Host Disease	Genotype TT is associated with decreased risk of Graft vs Host Disease when treated with cyclosporine and methotrexate in people with Hematopoietic stem cell transplantation as compared to genotypes CC + CT.		[ 25]
Methotrexate	N.A.	Graft Vs Host Disease	Genotype TT is associated with decreased risk of Graft vs Host Disease when treated with cyclosporine and methotrexate in people with Hematopoietic stem cell transplantation as compared to genotypes CC + CT.		[ 25]
Genetic Polymorphism	rs7499
Site of GPD	chr21:45512414 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A
Minor Allele Frequency	G=0.5370/1062 (Global)
Allele G	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Methotrexate	N.A.	Thrombocytopenia	Allele G is not associated with response to methotrexate in people with Arthritis, Rheumatoid as compared to allele A.		[ 17]
Methotrexate	N.A.	Adverse Events	Allele G is not associated with risk of adverse events due to methotrexate in people with Arthritis, Rheumatoid as compared to allele A.		[ 17]
Allele A	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Methotrexate	N.A.	Drug Toxicity	Allele A is associated with increased likelihood of treatment inefficacy when treated with methotrexate in people with Arthritis, Rheumatoid as compared to allele G.		[ 13]
Genetic Polymorphism	rs2838956
Site of GPD	chr21:45525110 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	A>C / A>G / A>T
Minor Allele Frequency	A=0.4520/894 (Global)
Allele G	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Methotrexate	N.A.	Thrombocytopenia	Allele G is not associated with response to methotrexate in people with Arthritis, Rheumatoid as compared to allele A.		[ 17]
Methotrexate	N.A.	Drug Toxicity	Allele G is associated with increased likelihood of treatment inefficacy when treated with methotrexate in people with Arthritis, Rheumatoid as compared to allele A.		[ 13]
Genotype GG	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Methotrexate	N.A.	Adverse Events	Genotype GG is associated with decreased risk of adverse events due to methotrexate in people with Arthritis, Rheumatoid as compared to genotypes AA + AG.		[ 17]
Methotrexate	N.A.	Rheumatoid Arthritis	Genotype GG is associated with decreased risk of adverse events due to methotrexate in people with Arthritis, Rheumatoid as compared to genotypes AA + AG.		[ 17]
Genotype AA	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Methotrexate	N.A.	Adverse Events	Patients with rheumatoid arthritis and the AA genotype may have an increased risk of experiencing adverse events as compared to patients with the GG genotype. However, this association did not reach statistical significance. Other genetic and clinical factors may also affect a patient's risk of experiencing methotrexate-related adverse events.		[ 17]
Methotrexate	N.A.	Rheumatoid Arthritis	Patients with rheumatoid arthritis and the AA genotype may have an increased risk of experiencing adverse events as compared to patients with the GG genotype. However, this association did not reach statistical significance. Other genetic and clinical factors may also affect a patient's risk of experiencing methotrexate-related adverse events.		[ 17]
Genotype AG	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Methotrexate	N.A.	Adverse Events	Patients with rheumatoid arthritis and the AG genotype may have an increased risk of experiencing adverse events as compared to patients with the GG genotype. However, this association did not reach statistical significance. Other genetic and clinical factors may also affect a patient's risk of experiencing methotrexate-related adverse events.		[ 17]
Methotrexate	N.A.	Rheumatoid Arthritis	Patients with rheumatoid arthritis and the AG genotype may have an increased risk of experiencing adverse events as compared to patients with the GG genotype. However, this association did not reach statistical significance. Other genetic and clinical factors may also affect a patient's risk of experiencing methotrexate-related adverse events.		[ 17]
Genetic Polymorphism	rs3788200
Site of GPD	chr21:45536657 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	A>G / A>T
Minor Allele Frequency	A=0.4830/955 (Global)
Genotypes AG + GG	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Methotrexate	N.A.	Thrombocytopenia	Genotypes AG + GG are not associated with concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype AA.		[ 1]
Methotrexate	N.A.	Drug Toxicity	Genotypes AG + GG is associated with increased concentrations of methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype AA.		[ 54]
Allele G	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Methotrexate	N.A.	Drug Toxicity	Allele G is not associated with response to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele A.		[ 1]
Genotypes AA + AG	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Methotrexate	N.A.	Mucositis	Genotypes AA + AG are not associated with risk of mucositis when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.		[ 1]
Genetic Polymorphism	rs1131596
Site of GPD	chr21:45538002 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A
Minor Allele Frequency	G=0.5270/1042 (Global)
Genotypes AG + GG	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Methotrexate	N.A.	Thrombocytopenia	Genotypes AG + GG are not associated with concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype AA.		[ 1]
Methotrexate	N.A.	Mucositis	Genotypes AG + GG are not associated with risk of mucositis when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype AA.		[ 1]
Allele G	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Methotrexate	N.A.	Drug Toxicity	Allele G is not associated with response to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele A.		[ 1]
Methotrexate	N.A.	Progression-free Survival	Allele G is not associated with response to methotrexate in people with Arthritis, Rheumatoid.		[ 57]
Genetic Polymorphism	rs7279445
Site of GPD	chr21:45500004 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>T
Minor Allele Frequency	C=0.4240/839 (Global)
Allele T	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Methotrexate	N.A.	Drug Toxicity	Allele T is associated with increased likelihood of treatment inefficacy when treated with methotrexate in people with Arthritis, Rheumatoid as compared to allele C.		[ 13]
Genetic Polymorphism	rs11702425
Site of GPD	chr21:45488441 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>A / T>C / T>G
Minor Allele Frequency	T=0.6750/1335 (Global)
Allele C	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Methotrexate	N.A.	Drug Toxicity	Allele C is associated with increased likelihood of treatment inefficacy when treated with methotrexate in people with Arthritis, Rheumatoid as compared to allele T.		[ 13]
Genetic Polymorphism	rs17004785
Site of GPD	chr21:45512704 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A / G>C / G>T
Minor Allele Frequency	G=0.8930/1767 (Global)
Genotype CG	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Methotrexate	N.A.	Drug Toxicity	Genotype CG is associated with increased clearance of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.		[ 57]
Genetic Polymorphism	rs1051296
Site of GPD	chr21:45514947 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	A>C
Minor Allele Frequency	A=0.5110/1011 (Global)
Genotypes AC + CC	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Methotrexate	N.A.	Toxic Liver Disease	Genotypes AC + CC are associated with decreased concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype AA.		[ 58]
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Genotypes AC + CC are associated with decreased concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype AA.		[ 58]
Genotype AA	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Patients with acute lymphoblastic leukemia and the rs1051296 AA genotype may have increased concentrations of methotrexate as compared to patients with the AC or CC genotypes. This annotation only covers the pharmacokinetic relationship between rs1051296 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate concentrations.		[ 58]
Genotype AC	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Patients with acute lymphoblastic leukemia and the rs1051296 AC genotype may have decreased concentrations of methotrexate as compared to patients with the AA genotype. This annotation only covers the pharmacokinetic relationship between rs1051296 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate concentrations.		[ 58]
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Methotrexate	N.A.	Acute Lymphoblastic Leukemia	Patients with acute lymphoblastic leukemia and the rs1051296 CC genotype may have decreased concentrations of methotrexate as compared to patients with the AA genotype. This annotation only covers the pharmacokinetic relationship between rs1051296 and methotrexate and does not include evidence about clinical outcomes. Other genetic and clinical factors may also influence methotrexate concentrations.		[ 58]
References
1	Polymorphisms in methotrexate transporters and their relationship to plasma methotrexate levels, toxicity of high-dose methotrexate, and outcome of pediatric acute lymphoblastic leukemia. Oncotarget. 2017 Jun 6;8(23):37761-37772.
2	Effects of methylenetetrahydrofolate reductase and reduced folate carrier 1 polymorphisms on high-dose methotrexate-induced toxicities in children with acute lymphoblastic leukemia or lymphoma. J Pediatr Hematol Oncol. 2006 Feb;28(2):64-8.
3	Homocysteine, pharmacogenetics, and neurotoxicity in children with leukemia. J Clin Oncol. 2003 Aug 15;21(16):3084-91.
4	Influence of pre-hydration and pharmacogenetics on plasma methotrexate concentration and renal dysfunction following high-dose methotrexate therapy. Int J Hematol. 2013 Dec;98(6):702-7.
5	Effect of polymorphisms in folate-related genes on in vitro methotrexate sensitivity in pediatric acute lymphoblastic leukemia. Blood. 2005 Jul 15;106(2):717-20.
6	Pharmacogenetics of tenofovir clearance among Southern Africans living with HIV. Pharmacogenet Genomics. 2023 Jun 01;33(4):79-87.
7	Genetic factors involved in delayed methotrexate elimination in children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2021 May;68(5):e28858.
8	Polymorphisms within methotrexate pathway genes: Relationship between plasma methotrexate levels, toxicity experienced and outcome in pediatric acute lymphoblastic leukemia. Iran J Basic Med Sci. 2020 Jun;23(6):800-809.
9	Pharmacogenetic polymorphisms contributing to toxicity induced by methotrexate in the southern Spanish population with rheumatoid arthritis. OMICS. 2012 Nov;16(11):589-95.
10	Single nucleotide polymorphisms associated with methotrexate-induced nausea in juvenile idiopathic arthritis. Pediatr Rheumatol Online J. 2021 Apr 01;19(1):51.
11	Common polymorphisms in the folate pathway predict efficacy of combination regimens containing methotrexate and sulfasalazine in early rheumatoid arthritis. J Rheumatol. 2008 Apr;35(4):562-71.
12	Reduced folate carrier-1 80G>A polymorphism affects methotrexate treatment outcome in rheumatoid arthritis. Pharmacogenomics J. 2007 Dec;7(6):404-7.
13	Genetic polymorphisms in key methotrexate pathway genes are associated with response to treatment in rheumatoid arthritis patients. Pharmacogenomics J. 2013 Jun;13(3):227-34.
14	Polymorphism G80A in the reduced folate carrier gene and its relationship to methotrexate plasma levels and outcome of childhood acute lymphoblastic leukemia. Blood. 2002 Nov 15;100(10):3832-4.
15	Genetic polymorphisms of folate metabolic enzymes and toxicities of high dose methotrexate in children with acute lymphoblastic leukemia. Ann Hematol. 2007 Aug;86(8):609-11.
16	Polymorphisms in folate, pyrimidine, and purine metabolism are associated with efficacy and toxicity of methotrexate in psoriasis. J Invest Dermatol. 2007 Aug;127(8):1860-7.
17	Membrane-Spanning Protein Genetic Polymorphisms Related to Methotrexate Therapeutic Outcomes in a Chinese Rheumatoid Arthritis Population. J Clin Pharmacol. 2019 Nov;59(11):1471-1476.
18	A Pharmacokinetic and Pharmacogenetic Analysis of Osteosarcoma Patients Treated With High-Dose Methotrexate: Data From the OS2006/Sarcoma-09 Trial. J Clin Pharmacol. 2018 Dec;58(12):1541-1549.
19	Genetic polymorphisms in folate pathway enzymes as a possible marker for predicting the outcome of methotrexate therapy in Japanese patients with rheumatoid arthritis. J Clin Pharm Ther. 2009 Jun;34(3):355-61.
20	SLCO1B1 and SLC19A1 gene variants and irinotecan-induced rapid response and survival: a prospective multicenter pharmacogenetics study of metastatic colorectal cancer. PLoS One. 2013 Oct 15;8(10):e77223.
21	Association of MDR1 C3435T and RFC1 G80A polymorphisms with methotrexate toxicity and response in Jordanian rheumatoid arthritis patients. Int J Clin Pharmacol Ther. 2014 Sep;52(9):746-55.
22	The association of reduced folate carrier 80G>A polymorphism to outcome in childhood acute lymphoblastic leukemia interacts with chromosome 21 copy number. Blood. 2010 Jun 10;115(23):4671-7.
23	Methotrexate consolidation treatment according to pharmacogenetics of MTHFR ameliorates event-free survival in childhood acute lymphoblastic leukaemia. Pharmacogenomics J. 2012 Oct;12(5):379-85.
24	Impact of genetic variants of RFC1, DHFR and MTHFR in osteosarcoma patients treated with high-dose methotrexate. Pharmacogenomics J. 2015 Oct;15(5):385-90.
25	Cyclosporine and methotrexate-related pharmacogenomic predictors of acute graft-versus-host disease. Haematologica. 2015 Feb;100(2):275-83.
26	Influence of Methylenetetrahydrofolate Reductase C677T, A1298C, and G80A Polymorphisms on the Survival of Pediatric Patients with Acute Lymphoblastic Leukemia. Leuk Res Treatment. 2012;2012:292043.
27	Pharmacogenetics of platinum-based chemotherapy: impact of DNA repair and folate metabolism gene polymorphisms on prognosis of non-small cell lung cancer patients. Pharmacogenomics J. 2019 Apr;19(2):164-177.
28	An exploratory study by DMET array identifies a germline signature associated with imatinib response in gastrointestinal stromal tumor. Pharmacogenomics J. 2019 Aug;19(4):390-400.
29	G80A Single Nucleotide Polymorphism in Reduced Folate Carrier-1 Gene in a Mexican Population and its Impact on Survival in Patients with Acute Lymphoblastic Leukemia. Rev Invest Clin. 2016 May-Jun;68(3):154-62.
30	Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis. Arthritis Rheum. 2004 Sep;50(9):2766-74.
31	Contribution of common polymorphisms in reduced folate carrier and gamma-glutamylhydrolase to methotrexate polyglutamate levels in patients with rheumatoid arthritis. Pharmacogenetics. 2004 Nov;14(11):733-9.
32	Genetic polymorphisms associated with adverse events and elimination of methotrexate in childhood acute lymphoblastic leukemia and malignant lymphoma. J Hum Genet. 2007;52(2):166-71.
33	Association between reduced folate carrier G80A polymorphism and methotrexate toxicity in childhood acute lymphoblastic leukemia: a meta-analysis. Leuk Lymphoma. 2014 Dec;55(12):2793-800.
34	Effect of polymorphisms within methotrexate pathway genes on methotrexate toxicity and plasma levels in adults with hematological malignancies. Pharmacogenomics. 2014 Aug;15(11):1479-94.
35	Ancestry and pharmacogenetics of antileukemic drug toxicity. Blood. 2007 May 15;109(10):4151-7.
36	Pharmacogenetic evaluation of 6-mercaptopurine-mediated toxicity in pediatric acute lymphoblastic leukemia patients from aSouth Indian population. Pharmacogenomics. 2021 May;22(7):401-411.
37	Are gene polymorphisms related to treatment outcomes of methotrexate in patients with rheumatoid arthritis? A systematic review and meta-analysis. Pharmacogenomics. 2017 Jan;18(2):175-195.
38	Genetic Variation in. Pharmaceutics. 2024 Aug 17;16(8).
39	The impact of folate pathway variants on the outcome of methotrexate therapy in rheumatoid arthritis patients. Clin Rheumatol. 2024 Mar;43(3):971-983.
40	Evaluation of cytogenetic and molecular markers with MTX-mediated toxicity in pediatric acute lymphoblastic leukemia patients. Cancer Chemother Pharmacol. 2022 Mar;89(3):393-400.
41	Pharmacogenomic Markers of Methotrexate Response in the Consolidation Phase of Pediatric Acute Lymphoblastic Leukemia Treatment. Genes (Basel). 2020 Apr 24;11(4).
42	Polymorphisms of SLC19A1 80 G>A, MTHFR 677 C>T, and Tandem TS Repeats Influence Pharmacokinetics, Acute Liver Toxicity, and Vomiting in Children With Acute Lymphoblastic Leukemia Treated With High Doses of Methotrexate. Front Pediatr. 2020;8:307.
43	SLC19A1 80G allele as a biomarker of methotrexate-related gastrointestinal toxicity in Portuguese rheumatoid arthritis patients. Pharmacogenomics. 2014 Apr;15(6):807-20.
44	Pharmacogenetic and metabolite measurements are associated with clinical status in patients with rheumatoid arthritis treated with methotrexate: results of a multicentred cross sectional observational study. Ann Rheum Dis. 2005 Aug;64(8):1180-5.
45	Effects of SCT genetic polymorphisms on methotrexate concentrations and toxicities in Chinese children with acute lymphoblastic leukemia. Leuk Lymphoma. 2025 Jun;66(6):1068-1078.
46	Clinical-pharmacogenetic predictive models for MTX discontinuation due to adverse events in rheumatoid arthritis. Pharmacogenomics J. 2017 Oct;17(5):412-418.
47	Folate metabolic pathway single nucleotide polymorphisms: a predictive pharmacogenetic marker of methotrexate response in Indian (Asian) patients with rheumatoid arthritis. Pharmacogenomics. 2015 Dec;16(18):2019-34.
48	Genetic variants of thiopurine and folate metabolic pathways determine 6-MP-mediated hematological toxicity in childhood ALL. Pharmacogenomics. 2012 Jul;13(9):1001-8.
49	Influence of genetic polymorphisms in the folate pathway on toxicity after high-dose methotrexate treatment in pediatric osteosarcoma. Blood Res. 2016 Mar;51(1):50-7.
50	Influence of MTHFR and RFC1 polymorphisms on toxicities during maintenance chemotherapy for childhood acute lymphoblastic leukemia or lymphoma. J Pediatr Hematol Oncol. 2008 May;30(5):347-52.
51	Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426. J Clin Oncol. 2010 Feb 1;28(4):614-9.
52	Pharmacogenetics of pemetrexed combination therapy in lung cancer: pathway analysis reveals novel toxicity associations. Pharmacogenomics J. 2014 Oct;14(5):411-7.
53	XRCC1 R399Q polymorphism is associated with response to platinum-based neoadjuvant chemotherapy in bulky cervical cancer. Gynecol Oncol. 2006 Dec;103(3):1031-7.
54	Effects of genetic polymorphisms on methotrexate levels and toxicity in Chinese patients with acute lymphoblastic leukemia. Blood Sci. 2023 Jan;5(1):32-38.
55	Novel and replicated clinical and genetic risk factors for toxicity from high-dose methotrexate in pediatric acute lymphoblastic leukemia. Pharmacotherapy. 2023 Mar;43(3):205-214.
56	Transcription regulatory polymorphism -43T>C in the 5'-flanking region of SLC19A1 gene could affect rheumatoid arthritis patient response to methotrexate therapy. Rheumatol Int. 2007 Sep;27(11):1057-61.
57	Population pharmacokinetics of methotrexate in paediatric patients with acute lymphoblastic leukaemia and malignant lymphoma. Xenobiotica. 2022 Mar;52(3):265-273.
58	Effects of a microRNA binding site polymorphism in SLC19A1 on methotrexate concentrations in Chinese children with acute lymphoblastic leukemia. Med Oncol. 2014 Jul;31(7):62.

If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.